To review published studies on the effect of diabetes and its complications on utility scores to establish whether there is systematic variation across studies and to examine the implications for the estimation of quality-adjusted life years (QALYs).
A systematic review was performed using studies reporting QALY measures elicited from people with diabetes including those with a history of complications. Meta-analysis was used to obtain the average utility, and meta-regression was employed to examine the impact of study characteristics and elicitation methods on these values. The effect of different utility scores on QALYs was examined using diabetes simulation models.
In the meta-analysis based on 45 studies reporting 66 values, the average utility score was 0.76 (95% CI 0.75–0.77). A meta-regression showed significant variation due to age, method of elicitation and the proportion of males. The average utility score for individual complications ranged from 0.48 (95% CI 0.25, 0.71) for chronic renal disease to 0.75 (95% CI 0.73, 0.78) for myocardial infarction, and these differences produced meaningful changes in simulated QALYs. There was significant heterogeneity between studies.
We provide summary utility scores for diabetes and its major complications that could help inform economic evaluation and policy analysis.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Clarke, P. M., Gray, A. M., Briggs, A., et al. (2004). A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom prospective diabetes study (UKPDS 68) Outcomes Model. Diabetologia, 47, 1747–1759.
Palmer, A. J., Roze, S., Valentine, W. J., et al. (2004). The CORE diabetes model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (Type 1 and 2) to support clinical and reimbursement decision-making. Current Medical Research and Opinion, 20(Suppl), S5–S26.
Herman, W. H., Hoerger, T. J., Brandle, M., Hicks, K., Sorensen, S., Zhang, P., et al. (2005). Diabetes Prevention Program Research Group. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine, 142(5), 323–332.
EuroQol Group. (1990). EuroQol–a new facility for the measurement of health-related quality of life. Health Policy, 16(3), 199–208.
Horsman, J., Furlong, W., Feeny, D., & Torrance, G. (2003). The Health Utilities Index (HUI®): concepts, measurement properties and applications. Health and Quality of Life Outcomes, 1, 54.
Walters, S. J., & Brazier, J. E. (2003). What is the relationship between the minimally important difference and health state utility values? The case of the SF-6D. Health and Quality of Life Outcomes, 1, 4.
Torrance, G. W. (1986). Measurement of health state utilities for economic appraisal: A review. Journal of Health Economics, 5(1), 1–30.
Bharmal, M., & Thomas, J. (2006). Comparing the EQ-5D and the SF-6D Descriptive Systems to assess their ceiling effects in the US general population. Value in Health, 9(4), 262–271.
Barnett, T. E., Chumbler, N. R., Vogel, B. W., Beyth, R. J., Ryan, P., & Figueroa, S. (2007). The cost-utility of a car coordination/home telehealth programme for veterans with diabetes. Journal of Telemedicine and Telecare, 13(6), 318–321.
Douzdjian, V. (1998). Treatment strategies for insulin-dependent diabetics with ESRD: a cost-effectiveness. American Journal of Kidney Diseases, 31(5), 794–802.
Barofsky, I., Erickson, P., & Eberhardt, M. (2004). Comparison of a single global item and an index of a multi-item health status measure among persons with and without Diabetes in the US. Quality of Life Research, 13(10), 1671–1681.
Chancellor, J., Aballea, S., Lawrence, A., Sheldon, R., Cure, S., Plun-Favreau, J., et al. (2008). Preferences of patients with diabetes mellitus for inhaled versus injectable insulin regimens. Pharmacoeconomics, 26(3), 217–234.
Maddigan, S. L., Feeny, D. G., & Johnson, J. A. (2005). Health-related quality of life deficits associated with diabetes and comorbidities in a Canadian national population health survey. Quality of Life Research, 14(5), 1311–1320.
Sterne, J. A. C., Bradburn M. J., & Egger M. (2001) Meta-analysis in Stata. (Chapter 18) Resource document. Blackwell Publishing.
Hedges, L. V., Tipton, E., & Johnson, M. C. (2010). Robust variance estimation in meta-regression with dependent effect size estimates. Research Synthesis Methods, 1(1), 39–65.
Tengs, T. O., & Lin, T. H. (2003). A Meta-analysis of quality-of-life estimates for stroke. Pharmacoeconomics, 21(3), 191–200.
Maddigan, S. L., Feeny, D. H., Johnson, J. A., & Investigators., D. O. V. E. (2004). Construct validity of the RAND-12 and Health Utilities Index Mark 2 and 3 in type 2 diabetes. Quality of Life Research, 13(2), 435–448.
Maddigan, S. L., Majumdar, S. R., Guirguis, L. M., Lewanczuk, R. Z., Lee, T. K., Toth, E. L., et al. (2004). Improvements in patient-reported outcomes associated with an intervention to enhance quality of care for rural patients with type 2 diabetes. Diabetes Care, 27(6), 1306–1312.
Boye, K. S., Matza, L. S., Oglyesby, A., Malley, K., Kim, S., Hayes, R. P. & Brodows, R. (2006). Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes. Health and Quality of Life Outcomes, October 4, 80.
Currie, C. J., Morgan, C. L., Poole, C. D., Sharplin, P., Lammert, M., & McEwan, P. (2006). Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Current Medical Research and Opinion, 22(8), 1523–1534.
Huang, E. S., Shook, M., Jin, L., Chin, M. H., & Meltzer, D. O. (2006). The impact of patient preferences on the cost-effectiveness of intensive glucose control in older patients with new-onset diabetes. Diabetes Care, 29(2), 259–264.
Ose, D., Wensing, M., Szecsenyi, J., Joos, S., Hermann, K., & Miksch, A. (2009). Impact of primary care-based disease management on the health-related quality of life in patients with type 2 diabetes and comorbidity. Diabetes Care, 32(9), 1594–1596.
Farmer, A. J., Wade, A. N., French, D. P., Simon, J., Yudkin, P., Gray, A., et al. (2009). Blood glucose self-monitoring in type 2 diabetes: a randomised controlled trial. Health Technology Assessment, 13(15), 1–50.
Hammerschmidt, T., Zeitler, H. P., Gulich, M., & Leidl, R. (2004). A comparison of different strategies to collect standard gamble utilities. Medical Decision Making, 24(5), 493–503.
Shah, V. A., Gupta, S. K., Shah, K. V., Vinjamaram, S., & Chalam, K. V. (2004). TTO utility scores measure quality of life in patients with visual morbidity due to diabetic retinopathy or ARMD. Ophthalmic Epidemiology, 11(1), 43–51.
Lundkvist, J., Berne, C., Bolinder, B., & Jönsson, L. (2005). The economic and quality of life impact of hypoglycaemia. European Journal of Health Economics, 6(3), 197–202.
Wee, H. L., Li, S. C., Cheung, Y. B., Fong, K. Y., & Thumboo, J. (2006). The influence of ethnicity on health-related quality of life in diabetes mellitus: a population-based, multiethnic study. Journal of Diabetes and Its Complications, 20(3), 170–178.
Brown, S. E. S., Meltzer, D. O., Chin, M. H., & Huang, E. S. (2008). Perceptions of quality-of-life effects of treatments for diabetes mellitus in vulnerable and nonvulnerable older patients. Journal of the American Geriatrics Society, 56(7), 1183–1190.
Lloyd, A., Nafees, B., Gavriel, S., Rousculp, M. D., Boye, K. S., & Ahmad, A. (2008). Health utility values associated with diabetic retinopathy. Diabetic Medicine, 25(5), 618–624.
Sakthong, P., Charoenvisuthiwongs, R., & Shabunthom, R. (2008). A comparison of EQ-5D index scores using the UK, US and Japan preference weights in a Thai sample with type 2 diabetes. Health and quality of life outcomes, 23(6), 71.
McEwen, L. N., Kim, C., Haan, M. N., Ghosh, D., Lantz, P. M., Thompson, T. J., et al. (2009). Are health-related quality-of-life and self-rated health associated with mortality? Insights from translating research into action for diabetes (TRIAD). Primary Care Diabetes, 3(1), 37–42.
ADVANCE Collaborative Group. (2007). Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet, 370, 829–840.
Wexler, D. J., Grant, R. W., Wittenburg, E., Bosch, J. L., Cagliero, E., Delahanty, L., et al. (2006). Correlates of health-related quality of life in Type 2 diabetes. Diabetologia, 49, 1489–1497.
Levy, A. R., Christensen, T. L., & Johnson, J. A. (2008). Utility values for symptomatic non-severe hypoglycaemia elicited from persons with and without diabetes in Canada and the United Kingdom. Health and Quality of Life Outcomes, 29(6), 73.
Brown, M. M., Brown, G. C., Sharma, S., & Shah, G. (1999). Utility Values and Diabetic Retinopathy. American Journal of Ophthalmology, 128(3), 324–330.
Brown, G. C., Brown, M. M., Sharma, S., Brown, H., Gozum, M., & Denton, P. (2000). Quality of life associated with diabetes mellitus in an adult population. Journal of Diabetes and Its Complications, 14(1), 18–24.
Brown, M. M., Brown, G. C., Sharma, S., Landy, J., & Bakal, J. (2002). Quality of life with visual acuity loss from diabetic retinopathy and age-related macular degeneration. Archives of Ophthalmology, 120(4), 481–484.
Redekop, W. K., Koopmanschap, M. A., Stolk, R. P., Rutten, G. E., Wolffenbuttel, B. H., & Niessen, L. W. (2002). Health-related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes. Diabetes Care, 25(3), 458–463.
Sullivan, S. D., Lew, D. P., Devine, B. E., Hakim, Z., Reiber, G. E., & Veenstra, D. L. (2002). Health state preference assessment in diabetic peripheral neuropathy. Pharmacoeconomics, 20(15), 1079–1089.
Clarke, P., Gray, A., & Holman, R. (2002). Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Medical Decision Making, 22(4), 340–349.
Hart, H. E., Bilo, H. J. G., Redekop, W. K., Stolk, R. P., Assink, J. H., & Meyboom-de Jong, B. (2003). Quality of life of patients with type 1 diabetes mellitus. Quality of Life Research, 12(8), 1089–1097.
Sharma, S., Oliver-Fernandez, A., Bakal, J., Hollands, H., Brown, G. C., & Brown, M. M. (2003). Utilities associated with diabetic retinopathy: results from a Canadian sample. The British Journal of Ophthalmology, 87(3), 259–261.
Bagust, A., & Beale, S. (2005). Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Economics, 14(3), 217–230.
Wee, H. L., Cheung, Y. B., Li, S. C., Fong, K. Y., & Thumboo, J. (2005). The impact of diabetes mellitus and other chronic medical conditions on health-related quality of life: Is the whole greater than the sum of its parts? Health and Quality of Life Outcomes January, 3, 2.
Clarke, P. M., Simon, J., Cull, C. A., & Holman, R. R. (2006). Assessing the impact of visual acuity on quality of life in individuals with type 2 diabetes using the short form-36. Diabetes Care, 29(7), 1506–1511.
Morgan, C. L., McEwan, P., Morrissey, M., Peters, J. R., Poole, C., & Currie, C. J. (2006). Characterization and comparison of health-related utility in people with diabetes with various single and multiple vascular complications. Diabetic Medicine, 23(10), 1100–1105.
Sakamaki, H., Ikeda, S., Ikegami, N., Uchigata, Y., Iwamoto, Y., Origasa, H., et al. (2006). Measurement of HRQL using EQ-5D in patients with type 2 diabetes mellitus in Japan. Value in Health, 9(1), 47–53.
Supina, A. L., Feeny, D. H., Carroll, L. J., & Johnson, J. A. (2006). Misinterpretation with norm-based scoring of health status in adults with type 1 diabetes. Health and Quality of Life Outcomes, 16(4), 15.
Boye, K. S., Yurgin, N., Dilla, T., Cordero, L. A., Badia, X., Suriñach, N. L., et al. (2007). Health-related quality of life of patients with type 2 diabetes mellitus in primary care in Spain: self-reported and proxy assessment using the EQ-5D. Journal of Medical Economics, 10(1), 41–58.
Huang, E. S., Brown, S. E., Ewigman, B. G., Foley, E. C., & Meltzer, D. O. (2007). Patient perceptions of quality of life with diabetes-related complications and treatments. Diabetes Care, 30(10), 2478–2483.
Glasziou, P., Alexander, J., Beller, E., Clarke, P. M., & The ADVANCE Collaborative Group. (2007). Which health-related quality of life score? A comparison of alternative utility measures in patients with type 2 diabetes in the ADVANCE trial. Health and Quality of Life Outcomes, 27(5), 21.
Matza, L. S., Boye, K. S., Yurgin, N., Brewster-Jordan, J., Mannix, S., Shorr, J. M., et al. (2007). Utilities and disutilities for type 2 diabetes treatment-related attributes. Quality of Life Research, 16(7), 1251–1265.
Sullivan, P. W., Ghushchyan, V. H., & Ben-Joseph, R. (2008). The impact of obesity on diabetes, hyperlipidemia and hypertension in the United States. Quality of Life Research, 17(8), 1063–1071.
Vexiau, P., Mavros, P., Krishnarajah, G., Lyu, R., & Yin, D. (2008). Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France. Diabetes, obesity and metabolism, 10(Suppl, 1), 16–24.
Arne, M., Janson, C., Janson, S., Boman, G., Lindqvist, U., Berne, C., et al. (2009). Physical activity and quality of life in subjects with chronic disease: Chronic obstructive pulmonary disease compared with rheumatoid arthritis and diabetes mellitus. Scandinavian Journal of Primary Health Care, 27(3), 141–147.
Clarke, P. M., Hayes, A. J., Glasziou, P. G., Scott, R., Simes, J., & Keech, A. C. (2009). Using the EQ-5D index score as a predictor of outcomes in patients with type 2 diabetes. Medical Care, 47(1), 61–68.
Marrett, E., Stargardt, T., Mavros, P., & Alexander, C. M. (2009). Patient-reported outcomes in a survey of patients treated with oral antihyperglycaemic medications: associations with hypoglycaemia and weight gain. Diabetes, obesity and metabolism, 11(12), 1138–1144.
Zhang, X. H., Wee, H. L., Tan, K., Thumboo, J., & Li, S. C. (2009). Is diabetes knowledge associated with health-related quality of life among subjects with diabetes? A preliminary cross-sectional convenience-sampling survey study among English-speaking diabetic subjects in Singapore. Journal of Chinese Clinical medicine, 4(3), 144–150.
Mills, T., Law, S. K., Walt, J., Buchholz, P., & Hansen, J. (2009). Quality of Life in Glaucoma and Three Other Chronic Diseases. Drugs and Aging, 26(11), 933–950.
Imayama, I. (2009). Determinants of quality of life in adults with diabetes. Centre of Health Promotion Studies, School of Public Health. US: DPhil University of Alberta.
Cochran, J., & Conn, V. S. (2008). Meta-analysis of quality of life outcomes following diabetes self-management training. The Diabetes Educator, 34(5), 815–823.
Kind, P., Hardman, G. & Macran Susan. (1999) UK population norms for EQ-5D: Discussion Paper 172 The University of York, Centre for Health Economics.
Fryback, D. G., Dunham, N. C., Palta, M., Hammer, J., Buechner, J., Cherepanov, D., et al. (2007). US Norms for six generic health-related quality of life indexes from the national health measurement study. Medical Care, 45(12), 1162–1170.
Ariza-Ariza, R., Hernandez-Cruz, B., Carmona, L., Ruiz-Montesinos, M. D., Ballina, J., Navarro-Sarabia, F., et al. (2006). Assessing utility values in rheumatoid arthritis: A comparison between time trade off and the EuroQol. Arthritis Care & Research, 55(5), 751–756.
Ramon Luengo-Fernandez. (2009). Resource costs, health outcomes and cost effectiveness in stroke care: Evidence from the Oxford Vascular Study. DPhil, Oxford University, UK.
Liem, Y. S., Bosch, J. L., & Hunink, M. G. (2008). Preference-Based quality of life of patients on renal replacement therapy: A systematic review and meta-analysis. Value in Health, 11(4), 733–741.
National Institute for Clinical Excellence (NICE) (2004), Guide to the methods of technology appraisal, NICE, London.
Commonwealth of Australia. (1995). Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee: including economic analysis. Canberra: Department of Health and Community Services.
This report is independent research commissioned by the National Institute for Health Research. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health. We are grateful to Edmund Fitzgerald and Melanie Wyld for assistance with the literature review. In regard to other funding, AJH received support from an Australian National Health and Medical Research Council (NHMRC) Project Grant 512463; PMC was funded from an Australian NHMRC Career Development Award (571122). AH was funded from the NHMRC Screening a Test Evaluation Program Grant (633003).
Electronic supplementary material
Below is the link to the electronic supplementary material.
About this article
Cite this article
Lung, T.W.C., Hayes, A.J., Hayen, A. et al. A meta-analysis of health state valuations for people with diabetes: explaining the variation across methods and implications for economic evaluation. Qual Life Res 20, 1669–1678 (2011). https://doi.org/10.1007/s11136-011-9902-y
- Health-related quality of life
- Diabetes-related complications
- Simulation modelling